3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Neoplasms
2
Pancreatic Neoplasms
1
Neoplasm Metastasis
1
Multiple Endocrine Neoplasia Type 1
1
Lung Cancer Metastatic
1
Hyperlipoproteinemia Type II
1
Glioma
1
Glioblastoma
1
Coronary Disease
1
Carcinoma, Renal Cell
1
Carcinoma, Non-Small-Cell Lung
1
Atherosclerosis
1
Interventions
tremelimumab
1
regramostim
1
osimertinib
1
evolocumab
1
durvalumab
1
Radiotherapy
1
Radiation
1
Nivolumab
1
MLN 8237
1
Ipilimumab
1
Granulocyte-Macrophage Colony-Stimulating Factor
1
Cisplatin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Lung Cancer Metastatic
×
evolocumab
×
Clear all
NCT05144529
2026-05-05
TOP2101
Duke University
Phase 2
Terminated
19 enrolled
16 charts